A recent study published in the journal Human Gene Therapy evaluated the long-term survival and cardiac efficacy of the gene ...

Sarepta has acquired the global rights to develop ARO-DUX4 and ARO-DM1, two RNAi therapeutic candidates for types of muscular ...

Novartis's acquisition of Kate Therapeutics gives it a pipeline of gene therapies for three genetic neuromuscular diseases.

"Dune"-inspired Arrakis Therapeutics has tested its spice—an RNA-targeting small molecule—in a mouse model of myotonic ...

Columnist Patrick Moeschen, who lives with limb-girdle muscular dystrophy, explains why controlling what he can is so ...

After about five years working behind the scenes, Arrakis Therapeutics is unveiling that its lead program will aim to treat ...

On a crisp January evening in Park City, Utah, Hawken Miller, a content marketing specialist for wheelchair-maker Permobil, ...

A claims-based study revealed high adherence to phosphorodiamidate morpholino oligomer (PMO) treatments for Duchenne muscular dystrophy (DMD), but highlights limitations in interpreting real-world ...

Today GPM Investments, LLC launched the MDA Holiday Retail Campaign in support of Muscular Dystrophy Association’s (MDA) ...

An increase in research and development (R&D) activities in myotonic dystrophy is expected to drive market growth by ...

Duchenne muscular dystrophy (DMD) is an inherited muscle disease that causes weakness and atrophy (thinning of the muscles) throughout the body. This condition is not curable, but treatments can ...